Company: ABBV
Filing Date: 2025-03-10
Form Type: PRE 14A
Source: 0001558370-25-002603
Chunk: 37

Company: AbbVie Inc.
Filing Date: 2025-03-10
Form: PRE 14A
Chunk 37
---
,500 |
| Scott T. Reents       | ​ |    1,320,000 | ​    |         120 | %     |           2,250,000 |
| Jeffrey R. Stewart    | ​ |    1,545,000 | ​    |         120 | %     |           2,900,000 |
| Azita Saleki-Gerhardt | ​ |    1,236,000 | ​    |         120 | %     |           2,100,000 |
| Timothy J. Richmond   | ​ |    1,236,000 | ​    |         120 | %     |           1,950,000 |

(1) Mr. Gonzalez’s target award value was prorated using the 165% target from January-June 2024 based on his role as CEO and the 140% target from July-December 2024 based on his role as Executive Chairman.

44 | 2025 Proxy Statement

| ​ | ​                      |
| ​ | EXECUTIVE COMPENSATION |

LONG-TERM INCENTIVES AND 2024 RESULTS The executive long-term (“LTI”) program design aligns AbbVie’s LTI compensation with key operational and financial initiatives, including sustained EPS growth and generation of superior investment returns relative to peers. In 2024, NEOs received annual LTI awards with the following characteristics: Long-Term Incentive Program

| ​                                             | ​ | ​                                   | ​ | ​                  |
| Award Type                                    |   | Metric                              |   | Performance Period |
| 40% Performance Shares                        | ​ | EPS 3‑Year Relative TSR Modifier    | ​ | 3 Years            |
| 40% Performance‑Vested Restricted Stock Units | ​ | Relative Return on Invested Capital | ​ | 3 Years            |
| 20% Non‑Qualified Stock Options               | ​ | Stock Price Appreciation            | ​ | 10‑year term       |

| ● | Performance Shares (40% of total LTI award)—These awards have the potential to vest at 0% to 250% of target after a three-year performance period and are earned based on company performance in earnings per share (EPS) and relative total stockholder return (TSR). TSR performance is measured relative to a group made up of companies that are constituents in either the S&P Pharmaceutical, Biotech, and Life Science Index or the NYSE Arca Pharmaceutical Index. Div